ArticleClinical case reports2025
Pathological Complete Response in a Rare Case of Rectal Small Cell Neuroendocrine Carcinoma Following Neoadjuvant Radiochemotherapy: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rectal neuroendocrine neoplasms are rare, aggressive tumors comprising a small fraction of rectal malignancies but with increasing incidence due to improved endoscopic detection. Small cell neuroendocrine carcinoma, a high-grade variant, poses significant diagnostic and therapeutic challenges due to its rapid progression and poor prognosis. We report a case of a 32-year-old male presenting with per-rectal bleeding and pain for 6 months. Imaging revealed an anorectal mass with locoregional lymphadenopathy. Histopathology confirmed poorly differentiated small cell neuroendocrine carcinoma (Grade 3) via immunohistochemistry, with a high Ki-67 index and neuroendocrine marker expression. The patient received neoadjuvant radiotherapy (59.4 Gray in 30 fractions over 6 weeks) with concurrent chemotherapy etoposide and cisplatin, followed by abdominoperineal resection. Postoperative histology showed a pathological complete response. This case underscores the importance of considering rectal neuroendocrine neoplasms in patients with persistent rectal symptoms and highlights the role of immunohistochemistry in diagnosis. Despite limited literature, our case supports the potential efficacy of neoadjuvant radiochemotherapy in tumor downstaging and improving surgical outcomes in poorly differentiated rectal neuroendocrine carcinoma. Early diagnosis, protocol-based neoadjuvant radiochemotherapy, and appropriate surgical intervention can lead to favorable outcomes in high-grade rectal neuroendocrine neoplasms. This case reinforces the need for awareness, guideline-based management, and long-term surveillance to optimize prognosis in these rare but aggressive tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.